Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Abingworth

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 168
Average round size
info
The average size of a deal this fund participated in
$38M
Portfolio companies 104
Rounds per year 3.36
Lead investments 21
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 70
Key employees 12
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Abingworth is the famous VC, which was founded in 1973. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.

Besides them, we counted 12 critical employees of this fund in our database.

Among the various public portfolio startups of the fund, we may underline Pharmion, Algeta, Senseonics The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Life Science, Biopharma.

Speaking about the real fund results, this VC is 3 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2014. Comparing to the other companies, this Abingworth performs on 18 percentage points more the average number of lead investments. The average startup value when the investment from Abingworth is 5-10 millions dollars. The important activity for fund was in 2009. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 deals per year.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Abingworth, startups are often financed by Versant Ventures, SR One, InterWest Partners. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Wellcome Trust, Frazier Healthcare Partners. In the next rounds fund is usually obtained by MPM Capital, InterWest Partners, Versant Ventures.

Read more

Funds with similar focus

Funds from United Kingdom
Funds with similar focus located in United Kingdom:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pathalys Pharma

Biopharma
Biotechnology
$150M18 Jan 2023 Raleigh, North Carolina, United States

Entact Bio

Biopharma
Biotechnology
Life Science
Medical
$81M06 Dec 2022 Watertown, Massachusetts, United States

Venatorx Pharmaceuticals

Biotechnology
Health Care
Medical
Pharmaceutical
$34M04 Apr 2022 Pennsylvania, United States

Anjarium Biosciences

Biotechnology
Pharmaceutical
$60M15 Sep 2021 Schlieren, Zurich, Switzerland

Effector Therapeutics

Biotechnology
Health Care
Medical
$60M26 Aug 2021 San Diego, California, United States

CymaBay Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$100M02 Aug 2021 Hayward, California, United States

Glycomine

Biotechnology
Pharmaceutical
Therapeutics
$35M23 Jun 2021 San Francisco, California, United States

Adaptate Biotherapeutics

Biotechnology
Health Care
Therapeutics
$17M19 Apr 2021 London, Ontario, Canada

X4 Pharmaceuticals

Biotechnology
Clinical Trials
Health Care
Pharmaceutical
Therapeutics
$55M19 Mar 2021 Cambridge, Massachusetts, United States
News
Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Abingworth?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: